Product Code: NE16-01-00-00-00
All-oral Regimens Revolutionize the Market
This research service focuses on antiviral therapeutics for the treatment of the hepatitis C virus (HCV). A global product and pipeline assessment is provided for marketed and investigational products and combination regimens for the treatment of HCV. Segmentation by drug class is provided, along with supporting information such as clinical trial timelines and results, key market developments, historical and projected launch timelines, and epidemiology. The information contained in this research was derived from published sources, including disease organizations; public health organizations; company publications including annual reports, SEC filings, and press releases; government public sources; and articles in scientific journals.
Table of Contents
1. EXECUTIVE SUMMARY
Executive Summary
- 1. Key Market Developments Since Q1 2013
- 2. Key Findings
- 3. Evolution of Standard of Care for HCV
- 4. Key Companies to Watch
2. METHODOLOGY AND SCOPE
Methodology and Scope
3. INTRODUCTION
Introduction
- 1. HCV Overview
- 2. Global Prevalence of Chronic HCV Infection by Region
- 3. Global HCV Genotype Distribution and Relative Prevalence
- 4. HCV Antiviral Market-Segmentation
- 5. HCV Antiviral Market-Segmentation (continued)
4. COMPETITIVE ANALYSIS
Competitive Analysis
- 1. Competitive Landscape-Marketed Products and Products in Development
- 2. Competitive Landscape-All-oral Regimens Late Stage Clinical Data
- 3. Competitive Landscape-Projected Launch Timeline for Oral Regimens
- 4. Competitive Landscape-Major Phase 3 Trials for All-oral Regimens
- 5. Competitive Landscape-Major Phase 3 Trials for All-oral Regimens (continued)
- 6. Competitive Landscape-Late Stage Assets by Company and Class
- 7. Marketed Products Synopsis-Standard of Care
- 8. Marketed Products Synopsis-Add-on to Standard of Care
- 9. Marketed Products Synopsis-Global Introduction by Region
- 10. Marketed Products Synopsis-Global Introduction by Region (continued)
- 11. Pipeline Synopsis-All-oral Regimens in Clinical Development
- 12. Pipeline Synopsis-All-oral Regimens in Clinical Development (continued)
- 13. Pipeline Synopsis-All-oral Regimens in Clinical Development (continued)
- 14. Pipeline Synopsis-Late Stage Clinical Development Landscape
- 15. Pipeline Synopsis-Late Stage Clinical Development Landscape (continued)
- 16. Pipeline Synopsis-Late Stage Clinical Development Landscape (continued)
- 17. Pipeline Synopsis-Late Stage Clinical Development Landscape (continued)
- 18. Pipeline Synopsis-Late Stage Clinical Development Landscape (continued)
- 19. Pipeline Synopsis-Late Stage Clinical Development Landscape (continued)
- 20. Pipeline Synopsis-Early Clinical Development Landscape
- 21. Pipeline Synopsis-Early Clinical Development Landscape (continued)
- 22. Pipeline Synopsis-Early Clinical Development Landscape (continued)
5. CONCLUSIONS AND RECOMMENDATIONS
Conclusions and Recommendations
- 1. Conclusions and Recommendations
- 2. Conclusions and Recommendations (continued)
- 3. Legal Disclaimer
6. APPENDIX
Appendix
- 1. Decision Support Database
- 2. Decision Support Database (continued)
- 3. Decision Support Database (continued)
- 4. Decision Support Database (continued)
7. THE FROST & SULLIVAN STORY
The Frost & Sullivan Story
- 1. The Frost & Sullivan Story
- 2. Value Proposition
- 3. Global Perspective
- 4. Industry Convergence
- 5. 360° Research Perspective
- 6. Implementation Excellence
- 7. Our Blue Ocean Strategy